IFNG and acute myeloid leukemia: However, further experimental validation that directly evaluates the impact of IFITM3 loss in an immunocompetent mouse model can shed further light on the direct impact of IFNγ-IFITM3 axis mediated from the tumor immune microenvironment on therapeutic resistance in AML.